RNAiScience logo

European Society for Paediatric Urology (ESPU) 2025

September 3-6, 2025 | Vienna, Austria

 

The material below is to support scientific exchange. Any content about investigational therapeutics or investigational uses of FDA-approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval. 

Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.

Long-term Effects of Lumasiran on Kidney Stones and Nephrocalcinosis in Patients with Primary Hyperoxaluria Type 1

Presentation

This site is intended for US healthcare professionals.
© 2025 Alnylam Pharmaceuticals, Inc. All rights reserved.
MED-US-ALL-2400001

RNAI Logo

You are now leaving this site and being directed to a third-party website that is not maintained by Alnylam. Alnylam does not endorse and is not responsible for content or maintenance of third-party websites.

ContinueCancel

RNAI Logo

You are now leaving this site and being directed to another Alnylam website.

ContinueCancel

RNAI Logo

Intended for US healthcare professionals. This site is intended to provide balanced, evidence-based information to support scientific exchange. It is not intended to provide medical advice or recommendations for clinical practice.

Information about investigational therapeutics or investigational uses of approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.

Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.

Are you a healthcare professional practicing in the United States?

I confirm I am a US healthcare professional

I am a US payer or healthcare decision maker

I am not a US healthcare professional, or a US payer or healthcare decision maker

I am an Alnylam Team Member